Back to School: How biopharma can reboot drug development. Access exclusive analysis here

FDA panel backs Xolair

An FDA advisory committee on Thursday voted 11-0 that Xolair omalizumab has a favorable risk benefit

Read the full 165 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE